UroGen Pharma Says FDA Approves Plan For Rolling NDA Submission For UGN-102 From January 2024

RTTNews | 756 gün önce
UroGen Pharma Says FDA Approves Plan For Rolling NDA Submission For UGN-102 From January 2024

(RTTNews) - Biotech company UroGen Pharma Ltd. (URGN) announced Tuesday that it has reached agreement with the U.S. Food and Drug Administration (FDA) on plans for submission of a New Drug Application (NDA) for UGN-102 (mitomycin) for intravesical solution.

The FDA indicated that the current clinical development plan for UGN-102, which includes evaluation of duration of complete response (CR) at 12 months from the pivotal ENVISION trial, will support submission of an NDA for the treatment of low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).

The FDA also agreed that the UGN-102 NDA can utilize a rolling review, allowing for early submission of the Chemistry, Manufacturing and Controls (CMC) sections of the NDA, which is planned for January 2024.

If approved, UGN-102 has the potential to introduce a new non-surgical treatment paradigm for LG-IR-NMIBC, a subset of bladder cancer patients characterized by high recurrence rates and the need for multiple surgeries.

The UGN-102 clinical development plan centers around the Phase 3 ENVISION pivotal trial and is supported by robust clinical data from the ATLAS Phase 3 and OPTIMA Phase 2b trials.

Etiketler: URGN
read more
UroGen Pharma Files Patent Infringement Lawsuit Against Teva Pharma

UroGen Pharma Files Patent Infringement Lawsuit Against Teva Pharma

Biotech company UroGen Pharma Ltd. (URGN) announced Wednesday that it has filed a lawsuit in the U.S. District Court for the District of Delaware against Teva Pharmaceuticals, Inc., Teva Pharmaceuticals USA, Inc., and Teva Pharmaceutical Industries, Ltd. (TEVA), alleging infringement of U.S. Patent Numbers 9,040,074 and 9,950,069.
RTTNews | 573 gün önce
European Shares Seen Tad Lower At Open

European Shares Seen Tad Lower At Open

European stocks may open a tad lower on Wednesday as investors await the Federal Reserve's interest-rate decision as well as earnings from the five "Magnificent Seven" companies for direction.
RTTNews | 53 dakika önce
European Economic News Preview: UK Mortgage Approvals Data Due

European Economic News Preview: UK Mortgage Approvals Data Due

Mortgage approvals data from the UK and flash GDP estimates from Spain are due on Wednesday, headlining a light day for the European economic news. At 3.00 am ET, Statistics Sweden releases preliminary GDP data for the third quarter. The economy is forecast to grow 0.8 percent sequentially after rising 0.5 percent a quarter ago.
RTTNews | 1s 4 dakika önce
Australian Market Sharply Extends Early Losses In Mid-market

Australian Market Sharply Extends Early Losses In Mid-market

The Australian stock market is sharply expending its early losses in mid-market moves on Wednesday, reversing the losses in the previous session, with the benchmark S&P/ASX 200 falling below the 8,950 level, despite the broadly positive cues from Wall Street overnight, as domestic inflation jumped higher-than-expected, with weakness in financial and technology stocks.>
RTTNews | 3s 2 dakika önce
Asian Markets Trade Mixed

Asian Markets Trade Mixed

Asian stock markets are trading mixed on Wednesday, following the broadly positive cues from Wall Street overnight, as traders remain cautious and are reluctant to make more significant moves ahead of the U.S. Fed's interest rate decision later in the day and are optimistic about a potential trade deal between the U.S. and China. Asian markets closed mostly lower on Tuesday.
RTTNews | 3s 26 dakika önce